Nominee List

Total Page：16

File Type：pdf, Size：1020Kb

NOMINEE LIST Best financial reporting (large cap) Cipla Hindalco Industries Hindustan Unilever Infosys Kotak Mahindra Bank Mahindra & Mahindra Piramal Enterprises Tata Steel Vedanta Best financial reporting (small to mid-cap) CEAT Everest Industries Hikal Hindustan Foods IIFL Finance KEC International Minda Industries Raymond The Phoenix Mills Zensar Technologies Best investor meetings (large cap) Bharti Airtel Hindustan Unilever Infosys Lupin Mahindra & Mahindra Piramal Enterprises Best investor meetings (mid-cap) Balkrishna Industries IIFL Finance Mindtree RPG Group Sterlite Technologies The Phoenix Mills NOMINEE LIST Best investor meetings (small cap) Amber Enterprises India Equitas Holdings Greenlam Industries Music Broadcast Navin Fluorine International NOCIL Raymond Zensar Technologies Best investor relations officer (large cap) Bharti Airtel Komal Sharan Bharti Airtel Aparna Vyas Garg Bharti Infratel Surabhi Chandna Cipla Naveen Bansal HDFC Conrad D'Souza Hindustan Unilever Suman Hegde Infosys Sandeep Mahindroo Kotak Mahindra Bank Nimesh Kampani Lupin Arvind Bothra Best investor relations officer (small to mid-cap) CEAT Pulkit Bhandari Jindal Steel & Power Nishant Baranwal Motilal Oswal Financial Services Rakesh Shinde PNB Housing Finance Deepika Gupta Padhi Raymond J Mukund RPG Group Pulkit Bhandari Schneider Electric Infrastructure Vineet Jain The Phoenix Mills Varun Parwal NOMINEE LIST Best investor relations team (large cap) Bharti Airtel Cipla Hindustan Unilever Infosys Kotak Mahindra Bank Larsen & Toubro Infotech Power Finance Corporation Vedanta Best investor relations team (mid-cap) Cyient Escorts Future Lifestyle Fashions Godrej Properties KEC International Minda Industries Motilal Oswal Financial Services Oberoi Realty PNB Housing Finance The Phoenix Mills Best investor relations team (small cap) CEAT Parag Milk Foods Raymond Schneider Electric Infrastructure Best use of media and technology Infosys Larsen & Toubro Infotech Mahindra & Mahindra The Phoenix Mills NOMINEE LIST Best engagement by an institutional investor BOI AXA Mutual Fund Ajay Khandelwal DSP Investment Managers Kaushal Maroo Franklin Templeton Mutual Fund Janakiraman Rengaraju HDFC Mutual Fund Chirag Setalvad IDFC Mutual Fund Arpit Kapoor Kotak Mutual Fund Pankaj Tibrewal L&T Mutual Fund Soumendra Nath Lahiri Reliance Mutual Fund Samir Rachh SBI Mutual Fund Sanjeev Patkar Sundaram Mutual Fund Krishna Kumar .

Copy Link

Recommended publications

Research Paper IJMSRR Impact Factor 0.348 E- ISSN - 2349-6746 ISSN -2349-6738
Research Paper IJMSRR Impact Factor 0.348 E- ISSN - 2349-6746 ISSN -2349-6738 A STUDY ON PERFORMANCE OF MAJOR IT COMPANIES OF INDIA Prof. (Dr). C.K.Madhusoodhanan Professor, Dept. of Management Studies, Sree Narayana Gurukulam College of Engineering, Kolenchery Kerala. A.V Rejimon Assistant Professor, Dept. of Management Studies, Sree Narayana Gurukulam College of Engineering, Kolenchery, Kerala. Introduction Globalisation, liberation and privatisation were initiated by the Narsimha Rao government in early nineties. The new economic policy of the government of India generated industrial growth. It led to unprecedented development of industries. I T industry became one of the most flourishing industries in India. The investment in I T Sector has increased since India opened up the economy for private sector. Emergence of Globalised economy witnessed growth of I T industry. Many new cooperates entered the industry. Different types of investors showed keen interest in investing in I T stocks because of the higher rate of return. In portfolio selection the investors are confronted with an issue of identifying the right company having intrinsic value for the investment. The issue to be discussed with is how to select the right company in the context of mushroom growth of IT companies with plenty of new entrance with little history but with great volume of profit. Literature Review The origin of Fundamental analysis for the share price valuation can be dated back to Graham and Dodd (1934) in which the authors have argued the importance of the fundamental factors in share price valuation. Theoretically, the value of a company, hence its share price, is the sum of the present value of future cash flows discounted by the risk adjusted discount rate.
[Show full text]
A STUDY on BEHAVIOUR PATTERN of DIVIDEND PAY-OUT: SELECTED BLUE-CHIP COMPANIES in INDIA Author Co - Author Dr.K.R.Sivabagyam A.Ranjitha Assistant Professor K
Compliance Engineering Journal ISSN NO: 0898-3577 A STUDY ON BEHAVIOUR PATTERN OF DIVIDEND PAY-OUT: SELECTED BLUE-CHIP COMPANIES IN INDIA Author Co - Author Dr.K.R.Sivabagyam A.Ranjitha Assistant Professor K. Madhu Varshini Department of Commerce N.Deekshithaa Sri Krishna Arts and Science College S. Kabilambika E-mail Id: [email protected] II M.Com Students MOB: 7871809789 E-mail Id: [email protected] [email protected] [email protected] [email protected] Mob: 9486939255; 9715184177; 9025868186 ABSTRACT Reliance Industries, Tata Consultancy services (TCS) and WIPRO in India and The term blue-chip was used to describe observe the behaviour pattern of the three high- priced stocks in 1923 when Oliver measures of dividend policy of the blue- Gingold, an employee at Dow Jones chip companies in India. observed certain stocks trading at $200 or more per share. Poker players bet in blue, KEYWORDS: Blue Chip Companies, white and red chips with blue chips having Dividend Policy, Investment Proposals. more value than both red and white chips. INTRODUCTION Today, blue chips stocks don’t necessarily refer to stocks with a high price tag, but In the exchange of India there are literally more accurately to stocks of high-quality thousands of companies but when it comes companies that have with stood the test of to financial stability only few companies time. A blue-chip company is a are financially stable and in other financial multinational firm that has been in aspects. Long term investors seek out for operation for a number of years.
[Show full text]
Nominee List
NOMINEE LIST Best financial reporting (large cap) Cipla Hindalco Industries Hindustan Unilever Infosys Kotak Mahindra Bank Mahindra & Mahindra Piramal Enterprises Tata Steel Vedanta Best financial reporting (small to mid-cap) CEAT Everest Industries Hikal Hindustan Foods IIFL Holdings KEC International Minda Industries Raymond The Phoenix Mills Zensar Technologies Best investor meetings (large cap) Bharti Airtel Hindustan Unilever Infosys Lupin Mahindra & Mahindra Piramal Enterprises Best investor meetings (mid-cap) Balkrishna Industries IIFL Holdings Mindtree RPG Group Sterlite Technologies The Phoenix Mills NOMINEE LIST Best investor meetings (small cap) Amber Enterprises India Equitas Holdings Greenlam Industries Music Broadcast Navin Fluorine International NOCIL Raymond Zensar Technologies Best investor relations officer (large cap) Bharti Airtel Komal Sharan Bharti Airtel Aparna Vyas Garg Bharti Infratel Surabhi Chandna Cipla Naveen Bansal HDFC Conrad D'Souza Hindustan Unilever Suman Hegde Infosys Sandeep Mahindroo Kotak Mahindra Bank Nimesh Kampani Lupin Arvind Bothra Best investor relations officer (small to mid-cap) CEAT Pulkit Bhandari Jindal Steel & Power Nishant Baranwal Motilal Oswal Financial Services Rakesh Shinde PNB Housing Finance Deepika Gupta Padhi Raymond J Mukund RPG Group Pulkit Bhandari Schneider Electric Infrastructure Vineet Jain The Phoenix Mills Varun Parwal NOMINEE LIST Best investor relations team (large cap) Bharti Airtel Cipla Hindustan Unilever Infosys Kotak Mahindra Bank Larsen & Toubro Infotech Power
[Show full text]
KOTAK EQUITY SAVINGS FUND Building No
KEY INFORMATION MEMORANDUM (KIM) 6th Floor, Kotak Infinity, KOTAK EQUITY SAVINGS FUND Building No. 21, Infinity Park, (An Open Ended Equity Scheme) Off. Western Express Highway, Gen.A.K. Vaidya Marg, Malad (E) Continuous Offer of scheme of Units available at NAV bases prices. Mumbai - 400 097. Riskometer 022-6638 4400 Moderate Moder [email protected] tely a a Name This product is suitable for investors who are seeking*: High tely Income from arbitrage opportunities in the equity market & long term capital growth assetmanagement.kotak.com ModerLow Kotak Equity Savings Fund Investment predominantly in arbitrage opportunities in the cash & derivatives segment of the equity market and equity & equity related securities High Low *Investors should consult their financial advisers if in doubt about whether the product is suitable for them. LOW HIGH Investors understand that their principal will be at moderately high risk Scheme Re-opened on October 17, 2014 This Key Information Memorandum (KIM) sets forth the information, which a prospective investor ought to know before investing. For further details of the scheme/Mutual Fund, due diligence certificate by the AMC, Key Personnel, investors’ rights & services, risk factors, penalties & pending litigations etc. investors should, before investment, refer to the Scheme Information Document and Statement of Additional Information available free of cost at any of the Investor Service Centres or distributors or from the website assetmanagemnt.kotak.com The Scheme particulars have been prepared in accordance with Securities and Exchange Board of India (Mutual Funds) Regulations 1996, as amended till date, and filed with Securities and Exchange Board of India (SEBI).
[Show full text]
Investor Presentation May 2016
Investor Presentation May 2016 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM Safe Harbor Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition. 2 Agenda Biocon: Who are we? Highlights • Business Highlights • Financial Highlights Growth Segments •
[Show full text]
Consumer Goods on Path to Recovery; Essentials Hold an Upper Edge Sector Update
Consumer Goods On path to recovery; Essentials hold an upper edge Sector Update Most consumer goods companies started Q4FY2020 with good growth, as Q4FY2020 Results Review gradual recovery was seen in the demand environment (especially in rural markets). However, the outbreak of COVID-19 resulted in a complete lockdown Sector: Consumer Goods in India in the last 10-15 days of March, leading to complete stoppage of production and disruption in supply chain. This impacted sales volumes of most Sector View: Positive companies at the fag end of the quarter, resulting in weak Q4FY2020 numbers. Volumes of most companies (barring food companies) under our coverage declined by 3-22% in Q4FY2020 (revenue of Sharekhan universe declined by 7.8% y-o-y). Companies such as Britannia Industries and Tata Consumer Products Our coverage universe (TCPL) registered growth of 2.5% and 5-6% (at organic level), respectively, in Q4FY2020. On the other hand, companies such as Godrej Consumer Products CMP PT Companies Reco. (Rs) (Rs) (GCPL), Emami, Jyothy Labs, and Dabur India posted double-digit decline in revenue, as pre-season inventory loading by dealers/distributors was affected Asian Paints 1,709 Buy 1,987 by the lockdown. On the international front, companies having large presence Britannia in Africa, Middle East and South East Asian countries registered lower sales in 3,623 Buy 4,060 Industries the international business affected by lockdown and macro headwinds. Lower raw-material prices (especially crude-linked inputs) and lower packaging costs Colgate- 1,383 Positive 1,551 aided gross margins of some companies to expand by 100-300 bps.
[Show full text]
Innovating with Infosys Finacle
PREFACE CUSTOMER CHANNEL/ PRODUCT SERVICE DISTRIBUTION INNOVATION INNOVATION INNOVATION INNOVATIVE INNOVATION CUSTOMS PROCESS IN PROJECT COMPONENT INNOVATION MANAGEMENT DEVELOPED Innovation continues to be the leitmotif of and felicitate our innovative partners. In this the global banking industry. A perfect storm booklet, I am proud to present the winners of of rising customer expectations, increasing the 2015 edition of the Infosys Finacle Client competitive pressures and stringent compliance Innovation Awards. demands is compelling more and more banks to In 2015, we received an overwhelming response pursue innovation for sustainable competitive in the form of 104 nominations across 6 advantage. innovation categories. Each nomination was Against this background, I am increasingly judged on the merits of the degree of innovation, enthused to see that many of our partners in the complexity of the initiative, and benefits financial services industry are leveraging Finacle delivered. Every nomination is an affirmation of solutions to develop deeper connections with how our clients are embracing breakthrough stakeholders, power continuous innovation, and innovations quickly to take advantage of global accelerate growth in the digital world. technology shifts and deliver differentiated products and services, based on their customers’ We instituted the Infosys Finacle Client unique requirements. Innovation Awards in 2014 to formally recognize 2 I External Document © 2016 EdgeVerve Systems Limited We found the entire process of inviting and
[Show full text]
Ultratech Corporate Dossier August
INDIA'S LARGEST CORPORATE CEMENT DOSSIER COMPANY Stock code: BSE: 532538 NSE: ULTRACEMCO Reuters: UTCL.NS Bloomberg: UTCEM IS / UTCEM LX Contents ADITYA BIRLA OPERATIONAL ECONOMIC INDIAN CEMENT ULTRATECH GROUP- AND FINANCIAL ENVIRONENT SECTOR LANDSCAPE OVERVIEW PERFORMANCE GLOSSARY Mnt – Million Metric tons Lmt – Lakhs Metric tons MTPA – Million Tons Per Annum MW – Mega Watts Q1 – April-June Q4 – January-March CY – Current year period LY – Corresponding Period last Year FY – Financial Year (April-March) ROCE – Return on Average Capital Employed ROIC – Return on Invested Capital 2 Note: The financial figures in this presentation have been rounded off to the nearest ` 1 cr. 1 US$ = ` 64.46 ADITYA BIRLA GROUP - OVERVIEW Aditya Birla Group – Overview Premium global US$ ~41 billion Corporation conglomerate In the League of Fortune 500 Operating in 36 countries with over 50% Group revenues from overseas Anchored by about 120,000 employees from 42 nationalities Ranked No. 1 corporate in the Nielsen’s Corporate Image Monitor FY15 # 1 cement player in India by Capacity A global metal powerhouse – 3rd biggest # 4 largest cement producers globally producers of primary aluminum in Asia (ex China) # 1 in viscose staple fibre in globally # 2 player in viscose filament yarn in India Globally 5th largest producer of acrylic Globally 4th largest producer of insulators fibre A leading player in life insurance and AM Indian Listed Entities Entities Listed Indian # 3 cellular operator in India Top fashion and lifestyle player in India Among top 2 supermarket chains in retail in India Our Values Integrity Commitment Passion Seamlessness Speed 4 UltraTech Cement India’s largest cement company No.
[Show full text]
CIPLA, Ltd. CIPLA Ltd Is a Pharmaceutical Company Based in India
CIPLA Ltd. And the Provision of Anti-AIDS Pharmaceuticals It’s 2001, and G. G. Brereton is a busy man. He heads the Global Intellectual Property Office at GlaxoSmithKline (GSK), a multinational pharmaceutical corporation with operations throughout the world. He is tasked with defending GSK’s patents against foreign imitators. In recent months he has been occupied with infringements against GSK patents for antiretroviral drugs – the pharmaceuticals used to treat the symptoms of HIV and AIDS. This week has been especially hectic: CIPLA Ltd. of India has just announced its offer to supply an antiretroviral “cocktail” to Sub-Saharan African countries for 3 percent of the price that GSK charges for its anti-AIDS cocktail. Top management at GSK wants options for responding to this surprising offer. G. G. has been given the job of (1) coming up with potential responses by GSK to this initiative and (2) identifying that option that best assures the continued profitability of the firm now and into the foreseeable future. He has till Friday to do it! HIV/AIDS. One of the most vexing public-health problems of the new century has been the explosion in cases of human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome (AIDS). In the year 2000, the United Nation AIDS Organization (UNAIDS) reported that 36.1 million people worldwide were living with HIV or AIDS. There were 5.3 million new cases of HIV infection in the year, and 3.0 million deaths attributable to HIV infection. Since its first diagnosis, the AIDS epidemic has claimed 21.8 million lives.
[Show full text]
Birla Group Holdings Private Limited: Rating Reaffirmed, Rated Amount Enhanced for Commercial Paper Programme
May 27, 2021 Birla Group Holdings Private Limited: Rating reaffirmed, rated amount enhanced for Commercial Paper Programme Summary of rating action Previous Rated Current Rated Instrument* Amount Amount Rating Action (Rs. crore) (Rs. crore) Commercial Paper (CP) Programme 3,500 4,000 [ICRA]A1+; assigned / reaffirmed Non-convertible debentures programme 500 0 [ICRA]AA- (stable); reaffirmed and withdrawn Non-convertible debentures programme 1,000 1,000 [ICRA]AA- (stable); reaffirmed Total 5,000 5,000 *Instrument details are provided in Annexure-1 Rationale The ratings factor in the position of Birla Group Holdings Private Limited (BGHPL) as one of the main holding companies of the Aditya Birla Group. The ratings factor in the company’s equity ownership of listed Group entities including Grasim Industries Limited (rated [ICRA]AAA(Stable)/A1+), Aditya Birla Capital Limited (rated [ICRA]AAA(Stable)/A1+), Aditya Birla Fashion and Retail Limited (rated [ICRA]AA(Stable) /A1+) and Hindalco Industries Limited. The ratings also factor in the company’s adequate liquidity position backed by the market value of its holdings in listed Group entities and its strategic holdings in non-listed Group companies (including other Group holding companies). Further, ICRA expects the Group to extend capital support to BGHPL, as and when required. The ratings are constrained by the standalone financials of the company and the negative net worth on its balance sheet. The outlook is Stable for the company. ICRA has reaffirmed and withdrawn the rating outstanding on non-convertible debenture programmes of BGHPL aggregating Rs. 500 crore in line with request received from the company.
[Show full text]
Monthly Market Outlook June 2021
Monthly Market Outlook June 2021 The views expressed in this presentation are through the period ending 07-June-21 and are subject to change at any time based on market and other conditions. This is not an offer or solicitation for the purchase or sale of any security and should not be construed as such. References to specific securities and issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Content Page Numbers Global Economy 4 Indian Economy 13 Equity Markets 30 Valuation 38 SIP Has Performed Well 43 Equity Investment Opportunity 47 Should We Invest In Gold ? 52 Interesting Facts About Crypto 56 Active V/S Passive Funds in Alpha Generation 60 Debt Market Outlook 65 Debt Investment Opportunity 75 Distributor Engagement 82 Annexure 87 Disclaimers & Disclosures 91 2 Equity Market Outlook June 2021 Global Economy 4 Debt At All Time High And Interest Burden At All Time Low Government Debt Government Interest Payments 5 Source: Fitch Ratings Fiscal And Monetary Stimulus Has Given Confidence To Businesses Source: The Conference Board, The Business Council, NBER 6 Stimulus Has Pushed Profit Margins To All Time High Levels Source: Bloomberg 7 Big Is Becoming Bigger Median profit margin for top 50 firms has rocketed higher Source: Bloomberg 8 Global Market Cap To GDP Ratio Rises To 131% Source: Bloomberg 9 High Corporate Issuances Reflects Investors Bullishness Source: Goldman Sachs, As of 31st March 2021 10 Commodities Are In Short Supply Shortage of commodities has pushed backwardation to nearly 15-year high Source: Bloomberg, CME, ICE, LME Note: Chart uses current BCOM constituents and weightings.
[Show full text]
Cipla Ltd (CIPLA)
Cipla Ltd (CIPLA) CMP: | 826 Target: | 975 (18%) Target Period: 12 months BUY January 30, 2021 Strong growth in India, RoW; better margins… Q3 revenues grew 18.2% YoY to | 5169 crore led by strong growth in domestic and RoW markets. Domestic sales grew 25.5% YoY to | 2231 crore. RoW markets business grew 47.2% YoY to | 823 whereas South Particulars Africa business fell 2.5% YoY to | 579 crore. US grew 9.6% YoY to | 1037 crore. EBITDA margins expanded 647 bps YoY to 23.8% mainly due to P articular Am ount significantly lower other expenditure. Hence, EBITDA grew 62.3% YoY to | Market Capitalisation | 66581 crore 1231 crore. PAT more than doubled to | 748 crore vs. | 351 crore in Q3FY20. Debt (FY20) | 2816 crore Cash (FY20) | 1004 crore Result Update Result Product launches, front-end shift key for formulation exports E V | 68393 crore 52 week H/L (|) 870/357 Formulation exports comprise ~54% of FY20 revenues. The company is E quity capital | 161.3 crore focusing on front-end model, especially for the US, along with a gradual shift from loss making HIV and other tenders to more lucrative respiratory and F ace value | 2 Price performance other opportunities in the US and EU. We expect export formulation sales to grow at 9.8% CAGR to | 12242 crore in FY20-23E. Key drivers will be a launch of inhalers (drug-device) and other products in developed markets. 1000 14000 12000 800 Indian formulations growth backed by new launches 10000 600 8000 With ~5% market share, Cipla is the third largest player in the domestic 400 6000 formulations market.
[Show full text]